ADAM17 and Alzheimer disease: We propose a synergistic role of Akt for both the inhibition of TACE-mediated shedding of TNFR1 and the activation of the UPR in mediating Aβ toxicity, which highlights the potential of Akt rather than PDK1 inhibitors for AD treatment.